A Superdevice for Mental Health
Arriving in 2025, OAK was born from 15 years of R&D, millions of hours of real-world Version 1.0 usage, and a relentless focus on making wearable brain stimulation not only scalable, but desirable. Proven as the most rapid self-administered treatment for depression and anxiety, and capable of improving a universe of conditions, OAK is designed to provide lifelong brain health.
Clinically Proven
The results of our 255-subject, triple-blind, randomized, controlled trial, published in The Journal of Clinical Psychiatry, prove our Version 2.0 wearable significantly reduces depression in the first week of treatment. A separate 220-subject, 8-week trial for the treatment of anxiety, conducted by the Seattle Police Department and Washington State University, achieved its primary endpoint and will be used to obtain regulatory clearance in the US and Europe in 2025 (journal publication is pending).
Proof-of-Concept
Under temporary FDA clearance, we distributed 100,000 proof-of-concept devices via 14,000 prescribers, and obtained Medicaid reimbursement in Maine (MaineCare). We are now engaged in obtaining regulatory approval for OAK, our Version 2.0 wearable that was designed in collaboration with the teams behind Beats, Nest and the HoloLens. Sign up to receive updates about OAK.
CEO
Kelly Roman
CO-FOUNDER, CEO, DIRECTOR
The son of a US Army veteran, Kelly graduated from Harvard College and has helped pioneer the wearable brain stimulation category since 2009, with a passion for clinical research, product development, regulatory affairs, manufacturing, and patient advocacy.
Kelly led OAK product development in collaboration with the teams behind Beats, Nest and the Microsoft HoloLens. Kelly also spearheaded the company's partnerships with the Seattle Police Department and Dr. Maurizio Fava, Psychiatrist-in-Chief of Massachusetts General Hospital, to design and conduct pivotal trials in support of regulatory approval.
Directors & Advisors
Chip Fisher
CO-FOUNDER, CHAIRMAN, DIRECTOR
After graduating from Harvard and serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s CFO and largest shareholder - and a recent TEDx contributor.
Simon Webster
ADVISOR
Simon is CEO of Vistra and founder of SHUFL Capital, a seed investing platform. He previously led CPA Global (IP software and services) as CEO through its merger with Clarivate.
Maurizio Fava, MD
ADVISOR
Dr. Fava is Psychiatrist-In-Chief, Department of Psychiatry, at Massachusetts General Hospital, and Director, Division of Clinical Research, at Mass General Research Institute.
David Shulkin, MD
ADVISOR
Dr. Shulkin is a former US Secretary of Veterans Affairs and a former CEO of Beth Israel Medical Center.
Michael Greenberg, MD, MPH, FACEP
MEDICAL ADVISOR
Mike is an emeritus professor of emergency medicine at Drexel University College of Medicine and a professor of public health in Drexel's Dornsife School of Public Health.
Scott Witt
ADVISOR
Scott is a Brand and Creative executive operator who previously served as Creative Director at Apple, advisor to Peloton and Chief Brand Officer at Twill.
Neil Leibowitz, MD, JD
ADVISOR
Neil recently served as Chief Medical Officer for two game-changing mental healthcare companies: Talkspace and Beacon Health Options.